Vistin Pharma ASA (LTS:0RAM) Change In Receivables: kr0.0 Mil (TTM As of Mar. 2026)


LTS:0RAM Vistin Pharma ASA LTS:0RAM
77 GF Score
Price kr20.70
GF Value kr25.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Change In Receivables?

Vistin Pharma ASA LTS:0RAM 77 Change In Receivables is kr0.0 Mil as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Vistin Pharma ASA's change in receivables for the quarter that ended in Mar. 2026 was kr0.0 Mil. It means Vistin Pharma ASA's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

Vistin Pharma ASA's change in receivables for the fiscal year that ended in Dec. 2025 was kr-6.6 Mil. It means Vistin Pharma ASA's Accounts Receivable increased by kr6.6 Mil from Dec. 2024 to Dec. 2025 .

Vistin Pharma ASA's Accounts Receivable for the quarter that ended in Mar. 2026 was kr100.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vistin Pharma ASA's Days Sales Outstanding for the three months ended in Mar. 2026 was 81.45.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vistin Pharma ASA's liquidation value for the three months ended in Mar. 2026 was kr19.7 Mil.

Vistin Pharma ASA  (LTS:0RAM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vistin Pharma ASA's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=100.162/112.214*91
=81.45

2. In Ben Graham's calculation of liquidation value, Vistin Pharma ASA's accounts receivable are only considered to be worth 75% of book value:

Vistin Pharma ASA's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=6.329-103.252+0.75 * 100.162+0.5 * 82.931
=19.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Change In Receivables Related Terms

Vistin Pharma ASA Change In Receivables Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Change In Receivables Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.05 44.57 -0.69 7.99 -6.62

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0RAM
77GF Score
Vistin Pharma ASA LTS:0RAM
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of kr0.0 Mil mean?
Vistin Pharma ASA (LTS:0RAM) has a Change In Receivables of kr0.0 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Change In Receivables too high?
Vistin Pharma ASA's current Change In Receivables is kr0.0 Mil. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Change In Receivables compare to ZTS and UTHR?
Vistin Pharma ASA's Change In Receivables of kr0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Change In Receivables is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Change In Receivables is kr0.0 Mil. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Change In Receivables is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Change In Receivables: kr0.0 Mil
  • GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score

Get the complete analysis for LTS:0RAM

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.70
Price
kr25.61
GF Value